Circulating adipokine concentrations and risk of five obesity‐related cancers: A Mendelian randomization study. Issue 7 (26th October 2020)

• Record Type: Journal Article
• Authors: Dimou, Niki L.; Papadimitriou, Nikos; Mariosa, Daniela; Johansson, Mattias; Brennan, Paul; Peters, Ulrike; Chanock, Stephen J.; Purdue, Mark; Bishop, D. Timothy; Gago‐Dominquez, Manuela; Giles, Graham G.; Moreno, Victor; Platz, Elizabeth A.; Tangen, Catherine M.; Wolk, Alicja; Zheng, Wei; Wu, Xifeng; Campbell, Peter T.; Giovannucci, Edward; Lin, Yi; Gunter, Marc J.; Murphy, Neil
• Is Part Of: International journal of cancer. Volume 148:Issue 7(2021)
• Page Start: 1625
• Page End: 1636
• Publication Date: 2020-10-26
• Subjects: adiponectin -- cancer -- leptin -- Mendelian randomization -- plasminogen activator inhibitor -- soluble leptin receptor; Cancer -- Periodicals; Cancer -- Prevention -- Periodicals; 616.994
• DOI: 10.1002/ijc.33338
• Languages: English
• ISSNs: 0020-7136

Abstract

Abstract: Obesity is considered a chronic inflammatory state characterized by continued secretion of adipokines and cytokines. Experimental and epidemiological evidence indicates that circulating adipokines may be associated with the development of obesity‐related cancers, but it is unclear if these associations are causal or confounded. We examined potential causal associations of specific adipokines (adiponectin, leptin, soluble leptin receptor [sOB‐R] and plasminogen activator inhibitor‐1 [PAI‐1]) with five obesity‐related cancers (colorectal, pancreatic, renal cell carcinoma [RCC], ovarian and endometrial) using Mendelian randomization (MR) methods. We used summary‐ level data from large genetic consortia for 114 530 cancer cases and 245 284 controls. We constructed genetic instruments using 18 genetic variants for adiponectin, 2 for leptin and 4 for both sOB‐R and PAI‐1 ( P value for inclusion<5 × 10 −8 ). Causal estimates were obtained using two‐sample MR methods. In the inverse‐variance weighted models, we found an inverse association between adiponectin and risk of colorectal cancer (odds ratio per 1 μg/mL increment in adiponectin concentration: 0.90 [95% confidence interval = 0.84‐0.97]; P = .01); but, evidence of horizontal pleiotropy was detected and the association was not present when this was taken into consideration. No association was found for adiponectin and risks of pancreatic cancer, RCC, ovarian cancer and endometrial cancer. Leptin, sOB‐R and PAI‐1 were also similarly unrelated to risk of obesity‐related cancers. Despite the large sample size, our MR analyses do not support causal effects of circulating adiponectin, leptin, sOB‐R and PAI‐1 concentrations on the development of five obesity‐related cancers. Abstract : What's new? Chronic inflammation attributed to obesity may influence cancer development. However, little is known about the relationship between oncogenesis and changes in adipokine secretion stemming from immune cell infiltration in adipose tissue. Here, large‐scale Mendelian randomization analysis was used to assess possible causal associations of adipokine concentrations influenced by genetic variation and risk of five obesity‐related cancers, including renal cell carcinoma and colorectal, pancreatic, ovarian and endometrial cancer. In general, no association was detected between adipokines and the five malignancies, suggesting that adipokine levels have no causal influence on these cancers.